PacBio and TychoBio Partner to Train AI Models for Rare Disease RNA Therapeutics

  • PacBio and TychoBio announced a collaboration to generate full-length RNA data for training AI models in RNA therapy design for rare diseases.
  • TychoBio plans to use PacBio HiFi sequencing and Kinnex long-read RNA sequencing to analyze over 10,000 samples.
  • The collaboration aims to build large-scale datasets linking steric blocking antisense oligonucleotides (SBOs) to their effects across the transcriptome.
  • PacBio's technology will help measure how RNA therapies change the transcriptome across multiple cell types, providing training data for predictive models.

This collaboration underscores the growing intersection of AI and genomics in drug discovery, particularly for rare diseases. PacBio's advanced sequencing technologies are becoming critical for generating high-quality data that powers AI-driven therapeutic design. The partnership aligns with broader industry trends towards precision medicine and the use of AI to tackle complex genetic disorders.

Data Quality
How the quality of PacBio's HiFi sequencing data will impact the accuracy of TychoBio's AI models.
Therapeutic Efficacy
Whether the collaboration can accelerate the development of safer and more efficient RNA therapeutics for rare diseases.
Market Expansion
The pace at which the approach will expand to other RNA-targeting compounds beyond SBOs.